McKesson Q2 FY2027 Results: Net Income $1.22 Billion on Revenue of $111 Billion
- US stocks
- Earnings
- Health Care

McKesson (NYSE: MCK) reported results for its fiscal 2027 second quarter, the quarter ended 30 Sep 2026, with revenue of $111.0 billion and net income attributable to McKesson of $1.22 billion (GAAP), and it said on 4 Nov 2026 that it had raised its full-year adjusted EPS guidance. Diluted EPS was $10.44 (GAAP), and the company's adjusted EPS, a company-defined measure that excludes certain items, was $11.68.
Key highlights
- Revenue (GAAP): $111.0 billion, up 7.6% YoY and 5.3% QoQ
- Net income attributable to McKesson (GAAP): $1.22 billion, up 9.7% YoY
- Diluted EPS (GAAP): $10.44, up 17.0% YoY
- Adjusted EPS (company-defined, non-GAAP): $11.68, up 18% YoY
- Fiscal 2027 adjusted EPS guidance (company-defined): $45.60 to $46.40
Summary
| Particulars | Q2 FY2027 | Q2 FY2026 | YoY | Q1 FY2027 | QoQ |
|---|---|---|---|---|---|
| Revenue | 110,957.0 | 103,150.0 | +7.6% | 105,380.0 | +5.3% |
| 1,604.0 | 1,407.0 | +14.0% | 1,319.0 | +21.6% | |
| Operating margin | 1.45% | 1.36% | +0.09 pp | 1.25% | +0.20 pp |
| 1,218.0 | 1,110.0 | +9.7% | 614.0 | +98.4% | |
| Net income margin | 1.10% | 1.08% | +0.02 pp | 0.58% | +0.52 pp |
| Diluted EPS ($) | 10.44 | 8.92 | +17.0% | 5.15 | +102.7% |
Figures are in $ million except EPS; YoY compares with Q2 FY2026 and QoQ with Q1 FY2027. Q2 FY2027 is the three months to 30 Sep 2026, from the company's release. Earlier quarters are checked against the company's SEC XBRL filings. GAAP; net income attributable to the company; diluted EPS. Changes and margins computed by Blacklitt.
The table shows GAAP revenue up 7.6% from a year earlier and up 5.3% from the first quarter of fiscal 2027. GAAP operating margin was 1.45%, against 1.36% a year earlier, a rise of 0.09 percentage points. Net income (GAAP) margin was 1.10%, against 1.08%.
Adjusted figures exclude acquisition amortization and one-off items
The company's adjusted earnings are a non-GAAP measure that excludes amortization of acquisition-related intangibles, transaction-related expenses, LIFO inventory-related adjustments, antitrust settlement gains, restructuring and certain other items. The release names $46 million of pre-tax charges tied to the planned separation of Medical-Surgical Solutions as one such item.
Adjusted profit rose in three of four segments
Oncology & Multispecialty revenue was $15.0 billion, up 24%, and its adjusted segment operating profit was $427 million, up 8%, against GAAP segment operating profit of $352 million. North American Pharmaceutical adjusted segment operating profit was $1.0 billion, up 22%. The company attributed the Medical-Surgical Solutions adjusted decline of 10% to lower contributions from the ambulatory care channel, which it said came from product mix.
The company reported $3.07 billion of operating cash flow for the quarter and $2.9 billion of free cash flow (company-defined, non-GAAP). It said it returned $3.6 billion to shareholders in the first six months, including $3.4 billion of share repurchases.
Fiscal 2027 adjusted EPS guidance raised to $45.60 to $46.40
The company raised its fiscal 2027 adjusted EPS guidance from $44.20 to $45.00 to $45.60 to $46.40, which it said indicates 17% to 19% growth. It does not forecast GAAP EPS, citing items it cannot reasonably forecast.
Inference
Diluted weighted-average shares were 116.7 million, down 6% from 124.4 million, and the company cited a lower share count among the drivers of adjusted EPS growth. Dividends declared were $0.94 per common share for the quarter, against $0.82 a year earlier.
The release does not give a dividend payment date. The next dated step is the Jefferies Global Healthcare Conference on 17 Nov 2026.
Filed with the US SEC on . Reference: Original filing (SEC)
Disclaimer:
The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.
Figures are from the company's filings with the US Securities and Exchange Commission and are in US dollars. Investing in US stocks from India is subject to the Liberalised Remittance Scheme, currency risk and taxes in both countries.

